On February 6, 2024, the Federal Trade Commission (“FTC”) commented in support of what would be a historic expansion of government march-in rights under the Bayh-Dole Act in response to the release of the National Institute...more
2/13/2024
/ Bayh-Dole Act ,
Draft Guidance ,
Drug Pricing ,
Federal Trade Commission (FTC) ,
Healthcare ,
Innovation ,
Inventions ,
March-in-Rights ,
NIST ,
Pharmaceutical Industry ,
Prescription Drugs ,
R&D ,
Regulatory Agenda ,
Regulatory Reform